Zacks Research Has Positive Estimate for TBPH Q1 Earnings

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Zacks Research lifted their Q1 2026 earnings estimates for Theravance Biopharma in a report issued on Thursday, April 9th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of $0.01 for the quarter, up from their prior forecast of ($0.15). Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share. Zacks Research also issued estimates for Theravance Biopharma’s Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at $0.62 EPS, FY2026 earnings at $0.80 EPS, Q1 2027 earnings at ($0.05) EPS, Q2 2027 earnings at ($0.03) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at $0.43 EPS and FY2027 earnings at $0.28 EPS.

TBPH has been the topic of several other research reports. Weiss Ratings lowered shares of Theravance Biopharma from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday. BTIG Research reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Theravance Biopharma in a research report on Friday, March 20th. TD Cowen lifted their price objective on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, March 23rd. Wall Street Zen raised shares of Theravance Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Finally, HC Wainwright lifted their price objective on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $21.83.

Theravance Biopharma Stock Performance

NASDAQ TBPH opened at $16.50 on Tuesday. The company has a market capitalization of $849.63 million, a PE ratio of 8.13 and a beta of 0.17. Theravance Biopharma has a 52-week low of $8.31 and a 52-week high of $21.03. The company has a 50-day simple moving average of $16.69 and a 200 day simple moving average of $17.09.

Institutional Trading of Theravance Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of TBPH. AQR Capital Management LLC bought a new stake in shares of Theravance Biopharma in the first quarter valued at approximately $101,000. Jane Street Group LLC raised its position in shares of Theravance Biopharma by 169.2% in the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock valued at $1,258,000 after purchasing an additional 88,540 shares during the period. Creative Planning bought a new stake in shares of Theravance Biopharma in the second quarter valued at approximately $139,000. American Century Companies Inc. raised its position in shares of Theravance Biopharma by 6.8% in the second quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company’s stock valued at $1,009,000 after purchasing an additional 5,794 shares during the period. Finally, Invesco Ltd. raised its position in shares of Theravance Biopharma by 12.4% in the second quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company’s stock valued at $279,000 after purchasing an additional 2,789 shares during the period. Institutional investors own 99.10% of the company’s stock.

Insider Buying and Selling

In other news, SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the transaction, the senior vice president owned 232,699 shares in the company, valued at $3,248,478.04. This trade represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 6.90% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.